None

Epigenomics AG gibt ein Update über sein Septin9-Programm im Rahmen eines Workshops zum Thema Darmkrebs-Screening bei der Jahrestagung 2012 der Vereinigung der Molekularpathologen (AMP) in den USA

Die Partner Quest Diagnostics und ARUP Laboratories berichten über ihre Erfahrungen mit...

G-BA agrees with IQWiG on Yervoy, Fampyra

Germany's Federal Joint Committee (G-BA) issued final assessments for Yervoy ipilimumab and Fampyra fampridine on Thursday that were in line with preliminary assessments from the Institute for Quality...

Human medicines European Public Assessment Report (EPAR): Fampyra, fampridine, Revision: 2, Authorised

Biogen Gets EU Panel OK for MS Drug

Weston, MA-based Biogen Idec (NASDAQ: BIIB) said today that it has received a positive opinion from a committee of the European Medicines Agency, which should pave the way to begin sales in Europe of...

Acorda Stock Soars on European Surprise

The European Medicine Agency (EMA) recommended conditional marketing authorization of Acorda Therapeutics’ (NASDAQ: ACOR) prolonged-release multiple sclerosis drug, fampridine (Fampyra), for t...

No Added Benefit Proven For Fampridine In MS

Drug manufacturer did not present evaluable study data on the appropriate comparator therapy Fampridine (trade name Fampyra®) has been approved in Germany since July 2011 for adult patients sufferin...

Added benefit of fampridine is not proven

Fampridine (trade name Fampyra) has been approved in Germany since July 2011 for adult patients suffering from a higher grade walking disability (grades 4 to 7 on the EDSS disability status scale), as...

[Regulus] to identify microRNA biomarkers for [Biogen Idec]

[Regulus Therapeutics Inc.] (a 2007 joint venture between [Alnylam] and [Isis]) will help [Biogen Idec Inc.] identify blood-borne microRNA biomarkers for multiple sclerosis. Biogen Idec will make an...

None